Sharaf El Din 2006.

Methods	Study design: parallel RC; possibly 3:1 however not well described Study duration: not reported Study follow‐up: 1 year
Participants	Country: Egypt Setting: single centre Inclusion criteria: LD kidney transplant recipients Number: treatment group (63); control group (20) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: not reported
Interventions	Treatment group Alemtuzumab: 20 mg, 2 doses day 0 and day 1 MP: 250 mg prior to each treatment CSA: 4 mg/kg/d from day 1 MMF: 500 mg twice daily from day 1 Control group MP: 250 mg in operating theatre at induction and at declamping PRED: with gradual decrease to 10 mg/d by 3 months CSA: 8 mg/kg/d from day 2 MMF: 1 g twice daily from day 2
Outcomes	Patient survival Graft survival Acute rejection SCr
Notes	Abstract‐only publication Not clear if randomised but states that it was Attempted to contact author to clarify methods but no response
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Unlikely to influence outcomes
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not clear if acute rejection was biopsy‐proven
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	Insufficient information to permit judgement